DSIP Dosage Guide: Research Protocols, Reconstitution and Timing
Delta sleep-inducing peptide (DSIP) is a nine-amino-acid peptide investigated for effects on sleep. Small human studies report both favorable and mixed findings; they do not establish a standard insomnia treatment protocol. This guide separates historical study regimens from the subcutaneous and nasal protocol claims readers encounter, checks concentration and syringe-volume arithmetic, and examines timing, cycling and safety uncertainties. Arithmetic accuracy is not clinical validation of a product or dose. For pharmacology and regulatory background, start with the DSIP peptide overview.
DSIP Dosage Chart: Quick Reference
This chart separates doses actually studied in humans from protocol figures previously listed on this page. It is not a personal dosing ladder. The six-volunteer crossover study and 16-patient insomnia trial used intravenous DSIP, not the subcutaneous or nasal products discussed online.
| Evidence or claim | Dose reported | Route | Timing reported | Interpretation |
|---|---|---|---|---|
| Healthy-volunteer crossover study | 25 nmol/kg | Slow intravenous infusion | Morning | Six participants; favorable short-term sleep findings |
| Chronic-insomnia parallel-group trial | 25 nmol/kg | Intravenous | Afternoons before laboratory nights 3, 4 and 5 | 16 patients; weak objective effects, no subjective sleep-quality improvement |
| Previously listed subcutaneous figures | 100; 200–300; 400–500 mcg | Subcutaneous | Previously presented as 30–60 min before bed | Not validated starter, standard or escalation tiers by these trials |
| Nasal protocols | No validated equivalent dose established here | Intranasal | No established bedtime schedule | Needle-free delivery does not establish efficacy or a dose conversion |
The Standard Research Dose
There is no established standard DSIP treatment dose for insomnia. The historical studies above investigated 25 nmol/kg intravenously; their findings do not validate a subcutaneous starting dose or maximum. The previously listed 100 mcg, 200–300 mcg and 400–500 mcg bands remain visible for comparison, but the cited trials do not establish them as starter, standard and non-responder tiers. A lower amount is not automatically a proven safe amount, and a lack of response does not establish a reason to escalate. Likewise, the previously mentioned 2–5 mg protocols should not be treated as validated regimens. Dose, route, formulation, study population and measured outcomes have to be evaluated together; numerical similarity alone does not make protocols equivalent.
Reconstitution and Dose Math
The concentration arithmetic can be checked without endorsing a preparation recipe. If 5 mg is present in a final solution volume of 2.5 mL, the concentration is 2 mg/mL (2,000 mcg/mL). Thus 0.05 mL contains 100 mcg and 0.1 mL contains 200 mcg. A U-100 syringe represents 100 units per mL, so these volumes are 5 and 10 units; units are not automatically the number of graduation lines. In the second example, 2 mg in a final volume of 2 mL is 1 mg/mL, and 0.1 mL contains 100 mcg. These are hypothetical mass/volume examples, not DSIP dose recommendations. The amount of diluent added need not equal the final solution volume. No universal choice of bacteriostatic water, mixing technique or four-week refrigerated shelf life follows from the math. The FDA chemistry review describes formulation- and environment-dependent stability; its discussion of bulk powder is not a validated beyond-use date for a finished vial. Obtain preparation, storage and beyond-use instructions specific to a legitimately dispensed product from its dispensing professional. Our peptide storage guide provides background, not DSIP-specific stability testing.
Timing Before Sleep
A fixed 30-to-60-minute bedtime window is not established by the human studies cited here. In a double-blind crossover study of six healthy volunteers, researchers gave 25 nmol/kg by slow intravenous infusion in the morning and reported increased sleep during the following 130 minutes and some subsequent nighttime improvements. A separate six-person chronic-insomnia study reported sleep-promoting effects beginning in the second hour after intravenous administration, not a predictable immediate bedtime effect. By contrast, a 16-patient double-blind trial used afternoon intravenous doses on three days: some objective measures improved, but effects were weak, subjective sleep quality did not improve, and the authors judged major short-term therapeutic benefit unlikely. These small studies retain a signal worth investigating, but do not determine timing for subcutaneous or nasal products. A circulating half-life alone also cannot establish the sleep-response window. Our how to inject peptides guide explains general technique; it does not establish a DSIP-specific route, timing or treatment protocol.
Injection vs Nasal
Injection and nasal spray are different delivery approaches, not interchangeable versions of an established DSIP insomnia treatment. The human sleep studies cited above used intravenous administration. The FDA review of human pharmacokinetics found limited intravenous information and no information for the proposed subcutaneous route. A known concentration and measured injection volume do not prove predictable systemic exposure, purity or clinical effect. Nasal absorption also requires product-specific evidence; there is no validated subcutaneous-to-nasal conversion in the studies discussed here. Needle-free convenience is a practical preference, not evidence that a nasal product works, and simply increasing its dose to compensate for presumed poor absorption is not evidence-based.
Cycling
The previously listed 5-to-14-night monthly pattern is not established as a tolerance-prevention schedule by the studies cited here. In a 14-person chronic-insomnia study, seven successive nights of DSIP were associated with improved sleep and daytime functioning, and sleep effects persisted on the first posttreatment placebo night. That favorable short-term observation does not establish long-term safety, absence of dependence or a tapering protocol. A separate four-night intravenous crossover study reported significant NREM sleep-time and stage-2 differences versus placebo, but the same differences were already present at baseline; its authors judged the sleep improvement of little clinical significance. Reports of changing response can be retained as anecdotes, but do not prove that scheduled breaks prevent tolerance. Nor is there adequate support here for a predictable mild rebound or mandatory taper. Discuss changes to a prescribed regimen with its prescriber; do not use DSIP protocols to guide withdrawal from other sleep medicines.
Side Effects and Safety
Some small intravenous studies reported good short-term tolerability, but that does not establish safety for ongoing subcutaneous or nasal use. The six-volunteer study reported no observed psychological, physiological or biochemical adverse effects. The 107-inpatient alcohol/opiate-withdrawal study abstract described good tolerability apart from headaches in a few patients. The FDA review of that study gives additional detail: transient sweating, headache, nausea and vertigo, plus hypotension cases; it also notes that withdrawal symptoms complicate interpretation. These findings should not be turned into an adverse-effect rate for people using DSIP for sleep. Vivid dreams, morning grogginess and injection-site irritation were previously presented here as usual complaints; the cited studies do not establish their frequency or prove that moving a dose earlier resolves them. If symptoms occur, review the product and other medicines rather than assuming they are a harmless adjustment. Sleep apnea deserves its own assessment: breathing pauses, gasping, loud snoring or daytime sleepiness are reasons to contact a healthcare professional, not evidence that DSIP treats or necessarily worsens apnea. This is editorial information, not clinical clearance. For the wider evidence, see peptides for sleep.
Legal and Research Status
DSIP is not an FDA-approved drug; the FDA briefing identifies neither emideltide free base nor emideltide acetate as a component of an approved drug. Both forms were considered at the July 24, 2026 advisory meeting. In the recorded free-base question and vote, six members favored inclusion on the 503A Bulks List, seven opposed it and one abstained. That is a recommendation against inclusion, not a final FDA rule. Advisory recommendations are nonbinding and do not themselves approve a drug or authorize compounding. The free-base tally should not be treated as verification of a separate acetate vote. A research-only label also does not authorize human treatment; availability is not proof of legal prescribing or compounding status. See the DSIP peptide overview for broader background. This guide reports evidence, not legal or clinical clearance.
Frequently Asked Questions About DSIP
There is no established standard DSIP dose for treating insomnia. Small historical human studies used 25 nmol/kg intravenously, with different populations and mixed sleep outcomes. The 100–500 mcg subcutaneous figures previously listed here are not validated starter, standard or escalation tiers by those trials. Neither those figures nor a milligram-dose protocol can be selected on the assumption that an online protocol is equivalent to a clinical trial.
There is no universal preparation recipe for every DSIP product. As arithmetic only, 5 mg in a final solution volume of 2.5 mL is 2 mg/mL: 0.05 mL contains 100 mcg and 0.1 mL contains 200 mcg. On a U-100 syringe those volumes correspond to 5 and 10 units, respectively; graduation lines vary by syringe. Similarly, 2 mg in a final volume of 2 mL is 1 mg/mL, so 0.1 mL contains 100 mcg. These calculations do not select a dose, diluent or storage period, and adding 2.5 mL is not necessarily the same as a final volume of 2.5 mL. Product-specific preparation, sterility and beyond-use information must come from a qualified dispensing professional; a research-only label does not establish suitability for injection.
There is no established DSIP bedtime schedule. Small human studies used intravenous administration, including morning infusions in six healthy volunteers and afternoon injections in a 16-patient insomnia trial. Results were mixed. Those studies do not validate a 30-to-60-minute bedtime window for subcutaneous or nasal products, and a circulating half-life cannot by itself establish when a sleep effect starts or ends.
Neither route has an established advantage for treating insomnia based on the studies cited here. The small human sleep trials discussed used intravenous DSIP, not a direct comparison of subcutaneous injection with nasal spray. A measured injected volume does not by itself establish how much active peptide reaches circulation or produces an effect. Nasal products cannot be assigned a higher equivalent dose without product-specific absorption and clinical data.
No validated monthly cycling or tapering schedule is established by the studies cited here. A small seven-night study reported sleep improvements that persisted on the first posttreatment placebo night, but this does not prove long-term freedom from tolerance, dependence or rebound. The previously listed 5-to-14-night monthly pattern is not a trial-validated schedule, and the claim that rebound is usually mild is not established. Decisions about stopping a prescribed product should be discussed with its prescriber, especially when other sleep medicines are involved.
The studies cited here do not establish the safety or benefit of combining DSIP with magnesium glycinate, glycine, L-theanine or prescription sleep medicines. Different proposed mechanisms do not prove that a combination is safe. Additive sedation with sedating medicines is a precaution to discuss, not a quantified DSIP-specific interaction demonstrated by these trials. Ask the clinician or pharmacist managing your medicines to review the full list rather than using a trial-and-error stacking sequence; do not stop prescribed sedatives abruptly based on this guide.
DSIP is not an FDA-approved drug. FDA considered emideltide free base and emideltide acetate at the July 24, 2026 advisory meeting. The verified free-base vote was six in favor of inclusion on the 503A Bulks List, seven against and one abstention: a recommendation against inclusion, not a final FDA rule. A committee recommendation does not itself grant drug approval or permission to compound, and a research-only label does not authorize human treatment. Product-specific legal questions require checking the current applicable rules, not inferring legality from availability.